[{"AccountsPayableCurrent_0_Q1_USD":1629000.0,"RealizedInvestmentGainsLosses_1_Q1_USD":0.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":524000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":664000.0,"ShortTermInvestments_0_Q1_USD":0.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":2000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":36103000.0,"LongTermNotesPayable_0_Q1_USD":3389000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q1_USD":4600000.0,"RepaymentsOfNotesPayable_1_Q1_USD":1000000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":13000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-8044000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":68000.0,"NotesPayable_0_Q1_USD":7366000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-8044000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q1_USD":828000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":81000.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":-2245000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":13000.0,"NonoperatingIncomeExpense_1_Q1_USD":95000.0,"InterestAndDebtExpense_1_Q1_USD":141000.0,"GainLossOnDispositionOfAssets1_1_Q1_USD":-11000.0,"ImpairmentOfLongLivedAssetsHeldForUse_1_Q1_USD":0.0,"DebtInstrumentUnamortizedDiscount_0_Q1_USD":27000.0,"AccretionExpense_1_Q1_USD":63000.0,"AccruedRentCurrent_0_Q1_USD":0.0,"SaleOfStockNumberOfSharesIssuedInTransaction_1_Q1_shares":2557544.0,"RestructuringReserve_0_Q1_USD":416000.0,"RestructuringCharges_1_Q1_USD":119000.0,"RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1_Q1_pure":0.5,"RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_1_Q1_position":44.0,"RestructuringAndRelatedCostCostIncurredToDate1_0_Q1_USD":2200000.0,"ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_1_Q1_USD":16000.0,"PaymentsToAcquireMarketableSecurities_1_Q1_USD":0.0,"PaymentsOfStockIssuanceCosts_1_Q1_USD":1068000.0,"PaymentsForRestructuring_1_Q1_USD":1218000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_1_Q1_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":266000.0,"OperatingLeaseLiability_0_Q1_USD":306000.0,"OperatingLeaseCost_1_Q1_USD":100000.0,"NumberOfOperatingSegments_1_Q1_segment":1.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":700000.0,"LesseeOperatingLeaseDiscountRate_0_Q1_pure":0.06,"IncomeTaxExaminationPenaltiesAndInterestExpense_1_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":11257000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q1_USD":36100000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":664000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":1000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q1_USD":16000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q1_shares":1895040.0,"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0_Q1_shares":7535815.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":0.0,"NetIncomeLoss_1_Q1_USD":-8044000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-8459000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":2001000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":17715000.0,"LiabilitiesCurrent_0_Q1_USD":8661000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":39050000.0,"Liabilities_0_Q1_USD":12050000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":-436000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":-104000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":410000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":2723000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.18,"CommonStockValue_0_Q1_USD":531000.0,"CommonStockSharesOutstanding_0_Q1_shares":53077348.0,"CommonStockSharesIssued_0_Q1_shares":53077348.0,"AssetsCurrent_0_Q1_USD":38341000.0,"Assets_0_Q1_USD":39050000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":12341000.0,"AdditionalPaidInCapital_0_Q1_USD":202685000.0,"AccountsReceivableNetCurrent_0_Q1_USD":4000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":2234000.0,"ClassOfWarrantOrRightOutstanding_0_Q1_shares":7535815.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":19754000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":443000.0,"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0_Q1_USD":1.13,"AccruedProfessionalFeesCurrent_0_Q1_USD":282000.0,"PropertyPlantAndEquipmentGross_0_Q1_USD":3817000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q1_USD":300000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q1_USD":3374000.0,"ShareBasedCompensation_1_Q1_USD":664000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":6103000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockSharesAuthorized_0_Q1_shares":5000000.0,"OperatingIncomeLoss_1_Q1_USD":-7998000.0,"OperatingExpenses_1_Q1_USD":8826000.0,"NotesPayableCurrent_0_Q1_USD":3977000.0,"InterestPaidNet_1_Q1_USD":61000.0,"DebtInstrumentCarryingAmount_0_Q1_USD":6667000.0,"CommonStockSharesAuthorized_0_Q1_shares":100000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.01,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":3055000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":45476338.0,"StockholdersEquity_0_Q1_USD":27000000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-176216000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_1_Q1_USD":1000.0,"UnrealizedGainLossOnInvestments_1_Q1_USD":0.0,"Ticker":"VRDN","CIK":"1590750","name":"MIRAGEN THERAPEUTICS, INC.","OfficialName":"Viridian Therapeutics Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"445189274.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200508"}]